Mari Ariyasu
0000-0002-5109-9448
Publication & Citation Trends
Most Cited Works
Publications
35 total
Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study PDF
Cited by 6
OpenAlex
Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study PDF
Cited by 8
OpenAlex
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults PDF
Cited by 7
OpenAlex
[Cefiderocol: a first and novel class of siderophore cephalosporin for Carbapenem-resistant Gram-negative infection]. OA
Cited by 1
Semantic Scholar
A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial. OA
Cited by 3
Semantic Scholar
Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1/2 priming and booster study OA
Cited by 1
Semantic Scholar
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults
Cited by 0
Semantic Scholar
Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan OA
Cited by 4
Semantic Scholar
Research Topics
Antibiotics Pharmacokinetics and Efficacy
(21)
Antibiotic Resistance in Bacteria
(19)
Antibiotic Use and Resistance
(11)
SARS-CoV-2 and COVID-19 Research
(10)
Urinary Tract Infections Management
(5)
Frequent Co-Authors
Affiliations
Shionogi (Japan)
Futaba (Japan)